bcl-2 and apoptosis in lymph node positive breast carcinoma

Cancer

Volumn 82, Issue 7, 1998, Pages 1296-1302

  Berardo, Melora D ^a   Elledge, Richard M ^b   De Moor, Carl ^c   Clark, Gary M ^b   Osborne, C Kent ^b   Allred, D Craig ^a  

^a Univ of Texas Health Science Center ^*  (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Bcl 2; Breast carcinoma; Prognosis

Indexed keywords

ANEUPLOIDY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; CYTOTOXICITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE;

EID: 0032055936     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980401)82:7<1296::AID-CNCR12>3.0.CO;2-1     Document Type: Article

References (34)

1. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990;10:5772-81.
2. Mercer WE, Shields MT, Amin M, Sauve GJ, Appela E, Romano JW, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A 1990;87:6166-70.
3. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent IM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
4. 1 cyclins. Cell 1993;73:1059-65.
5. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78:703-11.
6. Yonish-Rouach E, Resnitsky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352:345-7.
7. Dameshek W. Chronic lymphocytic leukemia: an accumulative disease of immunologically incompetent lymphocytes. Blood 1967;29:566-84.
8. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992;359:552-6.
9. Lu PJ, Lu QL, Rughetti A, Taylor-Papadimitriou J. bcl-2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorigenesis, of human mammary epithelial cells. J Cell Biol 1995;129:1363-78.
10. Warri AM, Huovinen RL, Laine AM, Martikainen PM, Härköen PL. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 1992;85:1412-8.
11. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989;49:5870-8.
12. Miyashita T, Reed JC. bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
13. Hsu B, Marin MC, Brisbay S, McConnell K, McDonnell TJ. Expression of bcl-2 gene confers multidrug resistance to chemotherapy-induced cell death. Cancer Bull 1994;46:125-9.
14. Dole M, Nuñez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, et al. bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994;54:3253-9.
15. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986;5:255-60.
16. Allred DC, Clark GM, Randon AK, McGuire WL. Immunohistochemistry on histologic sections from small (50 mg) samples of pulverized breast cancer. Histotech 1993;16:117-20.
17. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85: 200-6.
18. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988;61:420-7.
19. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-33.
20. Miyashita T, Harigai M, Hanada M, Reed I. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
21. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
22. Leek R, Kaklamanis L, Pezzella F, Gatter K, Harris A. bcl-2 in normal human breast and carcionoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994: 69:135-9.
23. Joensuu H, Pylkkänen L, Toikkanen S. bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-8.
24. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, et al. Expression of bcl-2 in primary breast cancer and its correlation with tumour phenotype. Ann Oncol 1994;5:409-14.
25. Gasparini G, Barbareschi M, Doglioni C, Palma P, Mauri F, Boracchi P, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995;1:189-98.
26. Hurlimann J, Larrinaga B, Vala D. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 1995;426:163-8.
27. Sierra A, Loveras B, Castellsague X, Moreno L, Garcia-Ramirez M, Fabra A. bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995;60:54-60.
28. Binder C, Marx D, Overhoff R, Binder I, Schauer A, Hiddemann W. bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 1995;6:1005-10.
29. Silvestrini R, Benini E, Veneroni S, Daidone M, Tomasic G, Squicciarini P, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996;14:1604-10.
30. Elledge R, Green S, Howes L, Clark G, Berardo M, Allred D, et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 1997;15:1916-22.
31. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994;30A:2068-73.
32. Oltvai ZN, Milliman CL, Korsmeyer SJ. bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-19.
33. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
34. Miyashita T, Krajewski S, Krajewska M, Wang H, Lin H, Liebermann D, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.